Spyre Therapeutics, Inc. SYRE Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months)
Available-for-Sale Debt Securities - Unrealized Loss Position (<12 Months) at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position (<12 months).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position (<12 months)?
- Spyre Therapeutics, Inc. (SYRE) reported available-for-sale debt securities - unrealized loss position (<12 months) of $432M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position (<12 months) changed year-over-year?
- Spyre Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position (<12 months) increased by 310.8% year-over-year, from $105.15M to $432M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position (<12 months)?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s available-for-sale debt securities - unrealized loss position (<12 months) has grown at a 93.0% compound annual growth rate (CAGR), from $25.17M to $180.96M.